Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 4 studies | 35% ± 13% |
Insufficient scRNA-seq data for expression of SPSB4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 91% | 119.82 | 2401 / 2642 | 99% | 13.78 | 695 / 705 |
pancreas | 100% | 979.38 | 328 / 328 | 42% | 0.91 | 75 / 178 |
lung | 87% | 89.12 | 504 / 578 | 17% | 1.20 | 196 / 1155 |
adrenal gland | 29% | 41.76 | 75 / 258 | 71% | 8.05 | 163 / 230 |
heart | 99% | 261.48 | 849 / 861 | 0% | 0 | 0 / 0 |
spleen | 95% | 332.24 | 230 / 241 | 0% | 0 | 0 / 0 |
kidney | 66% | 58.92 | 59 / 89 | 11% | 1.00 | 96 / 901 |
esophagus | 50% | 61.98 | 725 / 1445 | 26% | 1.11 | 47 / 183 |
breast | 31% | 22.59 | 144 / 459 | 26% | 0.86 | 287 / 1118 |
muscle | 53% | 60.67 | 428 / 803 | 0% | 0 | 0 / 0 |
intestine | 46% | 33.06 | 446 / 966 | 5% | 0.22 | 26 / 527 |
adipose | 51% | 55.32 | 613 / 1204 | 0% | 0 | 0 / 0 |
bladder | 33% | 26.33 | 7 / 21 | 8% | 0.69 | 39 / 504 |
uterus | 5% | 2.74 | 8 / 170 | 34% | 2.47 | 157 / 459 |
ovary | 2% | 1.18 | 4 / 180 | 34% | 1.98 | 147 / 430 |
thymus | 23% | 12.38 | 147 / 653 | 13% | 0.58 | 78 / 605 |
blood vessel | 25% | 15.21 | 332 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 24% | 2.46 | 11 / 45 |
skin | 14% | 13.79 | 259 / 1809 | 8% | 0.43 | 39 / 472 |
prostate | 20% | 16.18 | 48 / 245 | 1% | 0.08 | 4 / 502 |
liver | 16% | 9.11 | 36 / 226 | 4% | 0.09 | 16 / 406 |
stomach | 16% | 8.17 | 57 / 359 | 3% | 0.12 | 10 / 286 |
eye | 0% | 0 | 0 / 0 | 1% | 0.02 | 1 / 80 |
peripheral blood | 0% | 0.16 | 3 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1902916 | Biological process | positive regulation of protein polyubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0048511 | Biological process | rhythmic process |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0042752 | Biological process | regulation of circadian rhythm |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SPSB4 |
Protein name | SplA/ryanodine receptor domain and SOCS box containing 4 SPRY domain-containing SOCS box protein 4 (SSB-4) |
Synonyms | SSB4 |
Description | FUNCTION: Substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins . Negatively regulates nitric oxide (NO) production and limits cellular toxicity in activated macrophages by mediating the ubiquitination and proteasomal degradation of NOS2 . Acts as a bridge which links NOS2 with the ECS E3 ubiquitin ligase complex components ELOC and CUL5 . Diminishes EphB2-dependent cell repulsive responses by mediating the ubiquitination and degradation of EphB2/CTF2 . Regulates cellular clock function by mediating the ubiquitin/proteasome-dependent degradation of the circadian transcriptional repressor NR1D1 . . |
Accessions | ENST00000508126.1 H0Y8T2 Q96A44 ENST00000310546.3 |